AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22429066
Drug: Milnacipran 100
RxNorm normalized name: milnacipran 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran 100 mg/day continued
Trial: 22429066
Drug: Milnacipran 100
RxNorm normalized name: milnacipran 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran 100 mg/day discontinued
Trial: 19804497
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream (group A)
Trial: 18477073
Drug: Pre-operative oral
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative oral carbohydrate drink (400 ml, 2 hours before surgery)
Trial: 18477073
Drug: Pre-operative oral
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative oral carbohydrate drink
Trial: 2180659
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group using an algorithm for adjustment of insulin dosage based on daily prebreakfast capillary blood glucose measurements
Trial: 28762645
Drug: AHA-Ret Overnight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AHA-Ret Overnight Cream (double-conjugate retinoid cream)
Trial: 25884390
Drug: DHEA 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 75 mg once a day
Trial: 21988544
Drug: Problem-Solving Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-Solving Therapy
Trial: 17280527
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) replacement therapy, initially 2 microg/kg body weight/d, increased to a maximum of 12 microg/kg/d over 2 years.
Trial: 17280527
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) replacement therapy in men.
Trial: 17280527
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment in men.
Trial: 17280527
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) replacement therapy in women.
Trial: 17280527
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment in women.
Trial: 17280527
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) replacement therapy.
Trial: 11575340
Drug: Propofol 1‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1‐3 mg kg(‐1) h(‐1)
Trial: 9650878
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PDGF-BB and IGF-1 pre-treated dentine surface (group 4)
Trial: 9650878
Drug: TTC conditioned
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTC conditioned dentine surfaces treated with combination of PDGF-BB and IGF-1 (group 8)
Trial: 2649987
Drug: Cisplatin, etoposide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin, etoposide, and ifosfamide combination
Trial: 2649987
Drug: Ifosfamide in
RxNorm normalized name: ifosfamide Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide in first-line treatment
Trial: 339283
Drug: 15(S)15-methyl prostaglandin
RxNorm normalized name: 15(S)-15-Methyl Prostaglandin F2α
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15(S)15-methyl prostaglandin F2alpha administered as a single intramuscular injection (0.6 mg)
Trial: 339283
Drug: 15(S)15-methyl prostaglandin
RxNorm normalized name: 15(S)-15-Methyl Prostaglandin F2α
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15(S)15-methyl prostaglandin F2alpha administered as vaginal suppositories (1.0 or 1.5 mg per suppository)
Trial: 339283
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection (Group I)
Trial: 339283
Drug: Vaginal suppositories
RxNorm normalized name: Miconazole Nitrate Vaginal Suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal suppositories (Group II)
Trial: 30024027
Drug: Auricular point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular point acupressure (APA) treatment along with sleep hygiene practices
Trial: 27067882
Drug: Real rTMS
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real rTMS (5-Hz, 10 daily sessions)
Trial: 25391168
Drug: Probiotics (Infloran:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Infloran: Lactobacillus acidophilus 1 x 10(9) and Bifidobacterium bifidum 1 x 10(9) organisms) at a dose of 125 mg/kg/dose twice a day for 6 weeks or until discharge
Trial: 21925682
Drug: Amitifadine 25
RxNorm normalized name: Amitifadine
DrugBank: Amitifadine (DB05964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitifadine 25 mg BID for 2 weeks, then 50 mg BID for 4 weeks
Trial: 17507743
Drug: Carbohydrate loading
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate loading (CHOL; 8.4 g x kg(‐1) x d(‐1) carbohydrate)
Trial: 17507743
Drug: Normal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal diet (NORM; 5.2 g x kg(‐1) x d(‐1) carbohydrate)
Trial: 17507743
Drug: Carbohydrate loading
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate loading (CHOL) in midluteal (ML) phase
Trial: 17507743
Drug: Normal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal diet (NORM) in midluteal (ML) phase
Trial: 16268966
Drug: Melatonin 3
RxNorm normalized name: melatonin 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 3 mg nocte
Trial: 8983335
Drug: Metyrapone (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metyrapone (24 h treatment)
Trial: 8983335
Drug: Hydrocortisone (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (24 h treatment)
Trial: 8983335
Drug: Placebo (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (24 h treatment)
Trial: 6295985
Drug: Intraperitoneal antiserum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal antiserum and multiagent chemotherapy
Trial: 22305828
Drug: Prasugrel-based antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel-based antiplatelet therapy for 12 months
Trial: 22305828
Drug: Prasugrel-based antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel-based antiplatelet therapy for 1 month (in stable patients with BMS)
Trial: 20226286
Drug: Ibandronate 150
RxNorm normalized name: ibandronate 150 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 150 mg/month
Trial: 14571283
Drug: Formulation A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation A: 2 x 500 mg paracetamol tablets (Laboratorios Belmac S.A.)
Trial: 14571283
Drug: Formulation B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation B: 1 x 1,000 mg paracetamol powder sachets (Laboratorios Belmac, S.A.)
Trial: 14571283
Drug: Formulation C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation C: 2 x 500 mg paracetamol film-coated tablets (Panadol, SmithKline Beecham)
Trial: 14571283
Drug: Formulation D:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation D: 2 x 500 mg paracetamol tablets (Tylenol, McNeil)
Trial: 14571283
Drug: Formulation E:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation E: 1 x 1,000 mg effervescent paracetamol tablets (Efferalgan, UPSA)
Trial: 6347752
Drug: Verapamil 200
RxNorm normalized name: verapamil 200 mg/24 hours oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 200 mg b.i.d.
Trial: 31596819
Drug: NLP-based models
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NLP-based models (Model 7, combination of Models 1 and 4)
Trial: 28845898
Drug: Venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine ER 75-mg capsule before RYGB
Trial: 28845898
Drug: Venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine ER 75-mg capsule after RYGB
Trial: 15611894
Drug: Nasal continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal continuous positive airway pressure (nCPAP) therapy
Trial: 11586699
Drug: Zolpidem (ivadal)
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zolpidem (ivadal) 10 mg once daily before sleep for 2 weeks
Trial: 1927064
Drug: Misoprostol 200
RxNorm normalized name: MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol 200 micrograms twice daily after meals
Trial: 31860407
Drug: Intravenous glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucocorticoids (IVGCs)
Trial: 31860407
Drug: Oral glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucocorticoids (OGCs)
Trial: 24989138
Drug: IV tedizolid
RxNorm normalized name: Tedizolid
DrugBank: Tedizolid (DB14569)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV tedizolid phosphate 100-400 mg
Trial: 24989138
Drug: IV tedizolid
RxNorm normalized name: Tedizolid
DrugBank: Tedizolid (DB14569)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV tedizolid phosphate 200 mg once/day for 7 days
Trial: 24989138
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of tedizolid phosphate 200 mg
Trial: 24989138
Drug: IV tedizolid
RxNorm normalized name: Tedizolid
DrugBank: Tedizolid (DB14569)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV tedizolid phosphate 200 mg
Trial: 20113145
Drug: Resilient appliance
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Resilient appliance therapy
Trial: 17976724
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab (0.5 mg) administered over a 2-year period
Trial: 17976724
Drug: First-eye model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-eye model of ranibizumab treatment
Trial: 17976724
Drug: Combined model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined model of ranibizumab treatment
Trial: 15990632
Drug: High energy
RxNorm normalized name: High energy formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High energy density feeds (oil added; caloric density = 35 kcal/100 g)
Trial: 15990632
Drug: Low energy
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low energy density feeds (without oil; caloric density = 20 kcal/100 g)
Trial: 10097838
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy (10 sessions)
Trial: 10097838
Drug: Individual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual therapy (10 sessions)
Trial: 8835624
Drug: Intravenous metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoprolol (10-15 mg i.v.)
Trial: 1596811
Drug: Homeopathic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic treatment (thuya 30 CH, antimonium crudum 7 CH, nitricum acidum 7 CH)
Trial: 22309265
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg iptakalim
Trial: 22309265
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg iptakalim
Trial: 22309265
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg iptakalim
Trial: 22309265
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg iptakalim (women)
Trial: 22309265
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg iptakalim (women)
Trial: 22309265
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg iptakalim (men)
Trial: 22309265
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg iptakalim (fasting and nonfasting)
Trial: 22309265
Drug: 5 mg,
RxNorm normalized name: Winrevair 45 MG, 2 Vial Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg, 10 mg, 20 mg iptakalim
Trial: 17822876
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus treatment
Trial: 8740602
Drug: Cognitive self-hypnosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive self-hypnosis (CSH) treatment
Trial: 3481557
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tumor markers (carcinoembryonic antigen, ferritin, cancer antigen 125, tissue polypeptide antigen)
Trial: 28914592
Drug: 0.2% HA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% HA gel
Trial: 25468576
Drug: Caudal 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal 0.25% levobupivacaine (Group L(0.25))
Trial: 25468576
Drug: Caudal 0.20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal 0.20% levobupivacaine (Group L(0.20))
Trial: 25468576
Drug: Caudal 0.20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal 0.20% levobupivacaine plus 2 μg/kg dexmedetomidine (Group LD)
Trial: 22289528
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of celecoxib and FOLFOX4 regimen (folinic acid‐fluorouracil‐oxaliplatin)
Trial: 16638737
Drug: CS‐706 (2‐
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS‐706 (2‐ to 800‐mg doses daily, up to 14 days)
Trial: 15580062
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml meal rich in fat
Trial: 15580062
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml meal rich in carbohydrate
Trial: 15580062
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml meal rich in protein
Trial: 11298548
Drug: Oral terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbinafine 250 mg daily (n = 30)
Trial: 11298548
Drug: Placebo (moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (moisturizing ointment) (n = 30)
Trial: 11233189
Drug: Pacemaker (DDD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacemaker (DDD) treatment
Trial: 4817683
Drug: Mobilization headed
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobilization headed by a physician with written and oral instructions
Trial: 24515943
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri 10^8 organisms once daily for 5 days
Trial: 20976769
Drug: B-vitamins (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-vitamins (daily folic acid 2 mg, vitamin B6 25 mg, vitamin B12 0.5 mg)
Trial: 15722810
Drug: Multidisciplinary rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary rehabilitation (rheumatologist and physical therapist intake and discharge, 18 group supervised exercise therapy sessions, 2 group pain and stress management lectures, 1 group education lecture, 1 group dietary lecture, and 2 massage therapy sessions)
Trial: 341689
Drug: Pyrogastrone (carbenoxolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrogastrone (carbenoxolone sodium with alginate antacid) for 8 weeks
Trial: 341689
Drug: Control (alginate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (alginate antacid alone, Gaviscon‐like)
Trial: 31981106
Drug: Netarsudil 0.02%/latanoprost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netarsudil 0.02%/latanoprost 0.005% fixed combination QD for 3 months
Trial: 23071195
Drug: Historical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical treatment group with standard, in-person LSVT LOUD
Trial: 18713796
Drug: Nasal spray
RxNorm normalized name: Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray treatment with Streptococcus sanguinis
Trial: 18713796
Drug: Nasal spray
RxNorm normalized name: Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray treatment with Lactobacillus rhamnosus
Trial: 9819038
Drug: Recombinant activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant activated factor VII (rFVIIa) continuous infusion
Trial: 9819038
Drug: Recombinant activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant activated factor VII (rFVIIa) with heparin
Trial: 9819038
Drug: Recombinant activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant activated factor VII (rFVIIa) with low‐molecular‐weight heparin (LMWH, enoxaparin)
Trial: 9819038
Drug: Recombinant activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant activated factor VII (rFVIIa) with saline solution
Trial: 9819038
Drug: Recombinant activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant activated factor VII (rFVIIa) continuous infusion systems
Trial: 7806134
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (0.625 mg daily for 21 days) administered at 8 p.m.
Trial: 7806134
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (0.625 mg daily for 21 days) administered at 8 a.m.
Trial: 6778331
Drug: Pulverized prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulverized prednisone tablets (5 mg)
Trial: 6778331
Drug: Concomitant sulfisoxazole
RxNorm normalized name: Sulfisoxazole
DrugBank: Sulfisoxazole (DB00263)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant sulfisoxazole suspension of 50 mg/kg/day twice daily
Trial: 30991720
Drug: Sofrito (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofrito (240 g/70 kg)
Trial: 20483003
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive craniopuncture combined with urokinase infusion therapy
Trial: 16154019
Drug: Drug-eluting stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stents (DES) - Cypher (n=264) and Taxus (n=281)
Trial: 16154019
Drug: Drug-eluting stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stents (DES) compared to Bare-metal stents (BMS)
Trial: 7555458
Drug: Antacids, Cimetidine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacids, Cimetidine, Ranitidine
Trial: 2190013
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B at a daily dose of 2,400 mg
Trial: 2190013
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B at a daily dose of 1,200 mg
Trial: 2190013
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B at a daily dose of 2,400 to 7,200 mg
Trial: 2190013
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B at a daily dose of 4,800 mg
Trial: 7317219
Drug: Systemic benzylpenicillin
RxNorm normalized name: benzylpenicillin
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic benzylpenicillin and flucloxacillin administered just before operation and one and six hours afterwards.
Trial: 31835186
Drug: Alcohol (Males:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (Males: 0.68 g/kg; Females: 0.60 g/kg)
Trial: 29180855
Drug: 0.025% capsaicin
RxNorm normalized name: CAPSAICIN 2.5 mg in 10 g TOPICAL PATCH [0.025% Capsaicin Patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025% capsaicin ointment
Trial: 25785658
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart (0.5‐1.5 IU/h) as a continuous subcutaneous insulin infusion (CSII) during transient hyperglycemia for 2 h (visit TH)
Trial: 25785658
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart (0.5‐1.5 IU/h) as a continuous subcutaneous insulin infusion (CSII) during continuous hyperglycemia for 12 h (visit CH)
Trial: 25785658
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart (0.5‐1.5 IU/h) as a continuous subcutaneous insulin infusion (CSII) during both visits